Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Weight Loss/Management

Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial

C. W. Le Roux; A. Astrup; F. Greenway; M. Krempf; R. Vettor; L. Shapiro Manning; S. K. Lilleore; K. Fujioka Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial Diabetologia
Insulin Resistance & Diabetes

Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial

C. W. Le Roux; M. Davies; J. P. Frias; P. N. Laursen; I. Lingvay; S. Machineni; A. Varbo; J. P. Wilding; S. O. Wallenstein; L. Perreault Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial Obesity facts
Metabolic Syndrome

Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes

C. W. Le Roux; D. C. W. Lau; K. Fujioka; F. Greenway; J. P. H. Wilding; P. B. Jacobsen; T. Skjoth; S. Madsbad Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes Diabetic medicine
Insulin Resistance & Diabetes

Liraglutide; A new hope for obese diabetics

A. Kumar; D. Kumar; S. Razzaque; A. Kumar; R. Kumar; M. I. Ghauri; M. Yaseen Liraglutide; A new hope for obese diabetics Journal of the Liaquat University of Medical and Health Sciences
Insulin Resistance & Diabetes

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

C. W. le Roux; A. Astrup; K. Fujioka; F. Greenway; D. C. W. Lau; L. Van Gaal; R. V. Ortiz; J. P. H. Wilding; T. V. Skjøth; L. S. Manning; X. Pi-Sunyer 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet
Insulin Resistance & Diabetes

Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?

A. Kokkinos; D. Tsilingiris; C. W. le Roux; F. Rubino; C. S. Mantzoros Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery? Metabolism
Insulin Resistance & Diabetes

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes

N. Irwin; P. R. Flatt Enteroendocrine hormone mimetics for the treatment of obesity and diabetes Curr Opin Pharmacol
Insulin Resistance & Diabetes

Amylin as a Future Obesity Treatment

B. Dehestani; N. R. Stratford; C. W. le Roux Amylin as a Future Obesity Treatment J Obes Metab Syndr
Appetite & Satiety Insulin Resistance & Diabetes

Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery

C. S. A; W. l. R. C; J. P. D Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery Obes Surg

Can we use calorie intake and food choice measurements to determine individual variation in weight loss success to liraglutide 3.0 mg A direct method of eating behaviour assessment

W. Al Najim; R. T. Al Najim; N. Kapoor; G. Iatroudis; B. Dehestani; A. Grannell; J. Murphy; C. W. Le Roux Can we use calorie intake and food choice measurements to determine individual variation in weight loss success to liraglutide 3.0 mg A direct method of eating behaviour assessment Obesity reviews

Older posts

Newer posts

← Previous Page1 … Page11 Page12 Page13 … Page20 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2024 ASOI